{"protocolSection": {"identificationModule": {"nctId": "NCT00760838", "orgStudyIdInfo": {"id": "2008/445"}, "secondaryIdInfos": [{"id": "IWT 070709"}], "organization": {"fullName": "University Hospital, Ghent", "class": "OTHER"}, "briefTitle": "AZISAST Study: AZIthromycin in Severe ASThma Study", "officialTitle": "The AZIthromycin in Severe ASThma (AZISAST) Study: a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy, Safety and Cost-effectiveness of Azithromycin as add-on Therapy in Adult Subjects With Severe Persistent Asthma, Who Remain Inadequately Controlled Despite GINA (2006) Step 4 or 5 Therapy", "acronym": "AZISAST"}, "statusModule": {"statusVerifiedDate": "2014-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-09-25", "studyFirstSubmitQcDate": "2008-09-25", "studyFirstPostDateStruct": {"date": "2008-09-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-10-22", "resultsFirstSubmitQcDate": "2014-06-25", "resultsFirstPostDateStruct": {"date": "2014-06-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-25", "lastUpdatePostDateStruct": {"date": "2014-06-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Ghent", "class": "OTHER"}, "collaborators": [{"name": "Agentschap voor Innovatie door Wetenschap en Technologie", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy, safety and cost-effectiveness of azithromycin as add-on therapy in adult subjects with severe persistent asthma, who remain inadequately controlled despite GINA (2006) step 4 or 5 therapy."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Inadequately controlled severe asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 109, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Azithromycin", "type": "EXPERIMENTAL", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards", "interventionNames": ["Drug: Azithromycin 250 mg"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Azithromycin 250 mg", "description": "Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks", "armGroupLabels": ["Azithromycin"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks", "armGroupLabels": ["placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of Participants With Severe Asthma Exacerbations", "description": "Severe asthma exacerbations are defined as severe asthma episodes for which a treatment with antibiotics or cortisone is administered for a minimum of 3 days.", "timeFrame": "from baseline to week 26"}], "secondaryOutcomes": [{"measure": "Proportion of Participants Using Rescue Medication From Baseline to Week 26", "description": "proportion of participants using rescue medication is defined as the the number of participants who had to use rescue medication from baseline untill week 26, independent on the number of times the medication had to be used.\n\nThis measure was conducted by averaging the proportion of participants using rescue medication from each week between baseline and week 26.", "timeFrame": "from baseline to week 26"}, {"measure": "Peakflow Measurements", "description": "change in peak expiratory volume peak expiratory volume is measured as a maximal expiration for 1 second", "timeFrame": "from baseline to week 26"}, {"measure": "Change in Forced Expiratory Volume in 1 Second", "timeFrame": "from baseline to week 26"}, {"measure": "Change in Total Score on Asthma Control Questionnaire (ACQ)", "description": "A simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.\n\nACQ has a multidimensional construct assessing symptoms (5 items--self-administred) and rescue inbronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff\n\nScaling of items: 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 categories for FEV1%)\n\nScores range between 0 (totally controlled) and 6 (severely uncontrolled).", "timeFrame": "from baseline to week 26"}, {"measure": "Change in Total Score on the Asthma-related Quality of Life (AQLQ)", "description": "A disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease\n\n32 items with 2-week recall: Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items)\n\n7-point Likert scale (7 = not impaired at all - 1 = severely impaired).\n\nScores range 1-7, with higher scores indicating better quality of life.", "timeFrame": "from baseline to week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. patients who have given written informed consent\n2. males or females of any race\n3. 18-75 years of age\n4. with the diagnosis of persistent asthma \u2265 1 year duration at screening and a history consistent with GINA step 4 or 5 clinical features\n5. receiving high dose ICS plus inhaled LABA for at least 6 months prior to screening\n6. patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations within the previous 12 months\n7. patients must be never-smokers or ex-smokers with a smoking history of \u2264 10 pack-years.\n\nExclusion Criteria:\n\n1. females who are pregnant or who are breastfeeding\n2. patients with severe bronchiectasis\n3. patients with active tuberculosis or non-tuberculous mycobacterial infections (NTM)\n4. patients with significant underlying medical conditions (e.g. infection, hematological disease, malignancy, neurologic, renal, hepatic, coronary heart disease or other cardiovascular disease, endocrinologic or gastrointestinal disease) within the previous 3 months\n5. who are unable to perform spirometry or complete a patient diary or complete questionnaires\n6. patients with known hypersensitivity to azithromycin or other macrolide antibiotics\n7. patients who's heart rate corrected QT interval is prolonged\n8. patients who have - in the judgement of the investigator - a clinically relevant laboratory abnormality\n9. patients currently treated with macrolide antibiotics or recent macrolide treatment (in the past twelve weeks)\n10. anti-IgE treatment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Guy Brusselle, MD, PhD", "affiliation": "University Hospital, Ghent", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Onze Lieve Vrouw Ziekenhuis Aalst", "city": "Aalst", "zip": "9300", "country": "Belgium", "geoPoint": {"lat": 50.93604, "lon": 4.0355}}, {"facility": "ZNA Middelheim", "city": "Antwerpen", "zip": "2020", "country": "Belgium", "geoPoint": {"lat": 51.21989, "lon": 4.40346}}, {"facility": "AZ Sint-Jan Brugge", "city": "Brugge", "zip": "8000", "country": "Belgium", "geoPoint": {"lat": 51.20892, "lon": 3.22424}}, {"facility": "Ghent University Hospital", "city": "Ghent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "AZ Groeninge", "city": "Kortrijk", "zip": "8500", "country": "Belgium", "geoPoint": {"lat": 50.82803, "lon": 3.26487}}, {"facility": "Universitair Ziekenhuis Leuven", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "AZ Heilig Hart Roeselare", "city": "Roeselare", "zip": "8800", "country": "Belgium", "geoPoint": {"lat": 50.94653, "lon": 3.12269}}]}, "referencesModule": {"references": [{"pmid": "34807989", "type": "DERIVED", "citation": "Undela K, Goldsmith L, Kew KM, Ferrara G. Macrolides versus placebo for chronic asthma. Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD002997. doi: 10.1002/14651858.CD002997.pub5."}, {"pmid": "23291349", "type": "DERIVED", "citation": "Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, Verleden G, Demedts IK, Verhamme K, Delporte A, Demeyere B, Claeys G, Boelens J, Padalko E, Verschakelen J, Van Maele G, Deschepper E, Joos GF. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013 Apr;68(4):322-9. doi: 10.1136/thoraxjnl-2012-202698. Epub 2013 Jan 3."}], "seeAlsoLinks": [{"label": "Website of the Ghent University Hospital", "url": "http://www.uzgent.be"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "FG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "54"}, {"groupId": "FG001", "numSubjects": "55"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "53"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "BG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "109"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "109"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53", "lowerLimit": "36", "upperLimit": "60"}, {"groupId": "BG001", "value": "53", "lowerLimit": "46", "upperLimit": "64"}, {"groupId": "BG002", "value": "53", "lowerLimit": "46", "upperLimit": "64"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "67"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "42"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Belgium", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "109"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Proportion of Participants With Severe Asthma Exacerbations", "description": "Severe asthma exacerbations are defined as severe asthma episodes for which a treatment with antibiotics or cortisone is administered for a minimum of 3 days.", "populationDescription": "intention to treat analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "proportion of participants", "timeFrame": "from baseline to week 26", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "OG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.52", "lowerLimit": "0.36", "upperLimit": "0.75"}, {"groupId": "OG001", "value": "0.55", "lowerLimit": "0.38", "upperLimit": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Participants Using Rescue Medication From Baseline to Week 26", "description": "proportion of participants using rescue medication is defined as the the number of participants who had to use rescue medication from baseline untill week 26, independent on the number of times the medication had to be used.\n\nThis measure was conducted by averaging the proportion of participants using rescue medication from each week between baseline and week 26.", "populationDescription": "intention to treat analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "proportion of participants", "timeFrame": "from baseline to week 26", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "OG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.24", "spread": "2.11"}, {"groupId": "OG001", "value": "0.08", "spread": "1.14"}]}]}]}, {"type": "SECONDARY", "title": "Peakflow Measurements", "description": "change in peak expiratory volume peak expiratory volume is measured as a maximal expiration for 1 second", "populationDescription": "intention to treat analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "from baseline to week 26", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "OG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"title": "morning Peak Expiratory Volume", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.77", "spread": "48.20"}, {"groupId": "OG001", "value": "-1.81", "spread": "54.27"}]}]}, {"title": "evening Peak Expiratory Volume", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.65", "spread": "78.68"}, {"groupId": "OG001", "value": "-0.81", "spread": "48.47"}]}]}]}, {"type": "SECONDARY", "title": "Change in Forced Expiratory Volume in 1 Second", "populationDescription": "intention to treat analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of baseline FEV1", "timeFrame": "from baseline to week 26", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "OG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"title": "pre-bronchodilatator FEV1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.90", "spread": "11.79"}, {"groupId": "OG001", "value": "-0.02", "spread": "10.06"}]}]}, {"title": "post-bronchodilatator FEV1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "1.29"}, {"groupId": "OG001", "value": "8.84", "spread": "12.50"}]}]}]}, {"type": "SECONDARY", "title": "Change in Total Score on Asthma Control Questionnaire (ACQ)", "description": "A simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.\n\nACQ has a multidimensional construct assessing symptoms (5 items--self-administred) and rescue inbronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff\n\nScaling of items: 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 categories for FEV1%)\n\nScores range between 0 (totally controlled) and 6 (severely uncontrolled).", "populationDescription": "intention to treat analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "from baseline to week 26", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "OG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12", "spread": "0.70"}, {"groupId": "OG001", "value": "-0.24", "spread": "0.93"}]}]}]}, {"type": "SECONDARY", "title": "Change in Total Score on the Asthma-related Quality of Life (AQLQ)", "description": "A disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease\n\n32 items with 2-week recall: Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items)\n\n7-point Likert scale (7 = not impaired at all - 1 = severely impaired).\n\nScores range 1-7, with higher scores indicating better quality of life.", "populationDescription": "intention to treat analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "from baseline to week 26", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards"}, {"id": "OG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "spread": "0.73"}, {"groupId": "OG001", "value": "0.32", "spread": "0.89"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "from randomisation to exit visit (during the whole study period, at least 24 weeks)", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo\n\n1x/day during 5 days 3x/week afterwards", "seriousNumAffected": 4, "seriousNumAtRisk": 54, "otherNumAffected": 39, "otherNumAtRisk": 54}, {"id": "EG001", "title": "Azithromycin", "description": "Azithromycin 250 mg\n\n1x/day during 5 days 3x/week afterwards", "seriousNumAffected": 7, "seriousNumAtRisk": 55, "otherNumAffected": 37, "otherNumAtRisk": 55}], "seriousEvents": [{"term": "deep venous trombosis", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 55}]}, {"term": "cerebrovascular accident", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 55}]}, {"term": "gastro-enteritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 55}]}, {"term": "asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 55}]}, {"term": "pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 55}]}, {"term": "acute myocardial infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 55}]}, {"term": "oesophagitis grade A", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 55}]}, {"term": "pseudoparalysis right shoulder", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 55}]}], "otherEvents": [{"term": "lower respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 34, "numAffected": 22, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 24, "numAffected": 17, "numAtRisk": 55}]}, {"term": "asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 41, "numAffected": 27, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 40, "numAffected": 26, "numAtRisk": 55}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}]}, {"term": "headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 55}]}, {"term": "diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 55}]}, {"term": "abdominal pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}]}, {"term": "vertigo", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}]}, {"term": "allergic reaction", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}]}, {"term": "elevated liver function event", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}]}, {"term": "thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}]}, {"term": "leucopenia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "dr. Brusselle Guy", "organization": "Ghent University Hospital", "email": "guy.brusselle@uzgent.be", "phone": "003293322604"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017963", "term": "Azithromycin"}], "ancestors": [{"id": "D000000900", "term": "Anti-Bacterial Agents"}, {"id": "D000000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M20132", "name": "Azithromycin", "asFound": "Treat", "relevance": "HIGH"}, {"id": "M4222", "name": "Anti-Bacterial Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}